The current US Supreme Court has no fundamental understanding of a range of medical, engineering, technological, or ...

THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024.

If you’re on the fence about investing in Amgen Inc or Pfizer Inc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision. Read on to ...

As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

(RTTNews) - Amgen Inc. (AMGN) reported earnings for its third quarter that increased from the same period last year and beat the Street estimates. The company's bottom line came in at $2.83 ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Amgen Inc.'s Q3 earnings — due 30th October -are unlikely to be a major upside catalyst due to tricky comparisons, increased R&D spending, and transitional phase challenges. Key patents expiring ...

THOUSAND OAKS, Calif., Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The ...

Today, a brief rundown of news from GSK and Amgen, as well as updates from Roche, AbbVie, and Marinus Pharmaceuticals that you may have missed. GSK is making its largest investment in U.S.

Repatha (evolocumab) is a prescription drug that’s used to treat some types of high cholesterol. It’s also used to lower certain heart-related risks. This drug isn’t known to interact with ...